In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.
Benefit and danger from immunotherapy in myasthenia gravis / Rodolico C.; Nicocia G.; Damato V.; Antonini G.; Liguori R.; Evoli A.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - STAMPA. - 42:4(2021), pp. 1367-1375. [10.1007/s10072-021-05077-6]
Benefit and danger from immunotherapy in myasthenia gravis
Liguori R.;
2021
Abstract
In the last years, significant advances have improved the knowledge of myasthenia gravis (MG) immunopathogenesis and have enabled to realize new molecules with a selective action targeting compounds of the immunological system. This review discusses emerging treatments for MG, including complement inhibitors, neonatal Fc receptor targeting agents, and B cell interfering drugs, focusing on benefit and danger. In the second section of the review, several related adverse events of immunotherapy, including MGonset, are debated.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
